Skip to main content
. Author manuscript; available in PMC: 2017 Dec 21.
Published in final edited form as: Cancer. 2017 Jul 14;123(22):4430–4439. doi: 10.1002/cncr.30883

Figure 3.

Figure 3

(A) Event-free survival (EFS) and (B) overall survival (OS) among patients aged <50 years treated with idarubicin and cytarabine with clofarabine (CIA), idarubicin and cytarabine with fludarabine (FIA), and an idarubicin and cytarabine (IA) historical cohort.